Rapport

W9 Gavi's Vaccine Investment Strategy (VIS)

Helen Rees

Bernadette Abela Ridder (WHO), Seth Berkley (Gavi), Katherind O'Brien (Johns Hopkins U.), Saad Omer (Emory U.)

Auteurs

Langues

  • Anglais

Année de publication

2016

Type

Rapport

Catégories

  • Initiatives mondiales

Organisations

  • Gavi, l'Alliance du vaccin

GVIRF-2016

Vous pouvez trouver plus d’informations sur "GVIRF-2016" dans les rubriques suivantes :

TitreAuteurAnnéeTypeLangue
W2 Comprehensive assessment of risks and benefits of vaccines: the example of DengueLucky Slamet, Stephen Thomas2023ReportAnglais
P4 Preparing for the next Infectious Disease EmergencyHelen Rees, Norman BaylorReportAnglais
P3 Evolving Global Vaccine MarketsAmie Batson2020ReportAnglais
W9.3 Maternal influenza vaccines: How has the VIS process influenced the research agendaSaad Omer2016PresentationAnglais
W9.2 What’s Next for Gavi's Vaccine Investment Strategy: RabiesBernadette Abela-Ridder2016PresentationAnglais
W9.1 How does Gavi make vaccine investment decisions?Judith Kallenberg2016PresentationAnglais
W8.3 Combination Vaccines: Benefits and RisksMelissa Malhame2016PresentationAnglais
W8.2 Combination Vaccines: Potential future statesPeter Dull2016PresentationAnglais
W8.1 Combination Vaccines: How and Why? Lessons LearnedMichel De Wilde2016PresentationAnglais
W7.3 Intestinal Microbiota and Enteric Vaccine DesignJames Fleckenstein2016PresentationAnglais
W7.2 The Nasal Microbiota: Diversity, Dynamicity, and Vaccine-mediated EffectsJane Deng2016PresentationAnglais
W7.1 The infant microbiome: Relevance to immune responsesMaría Gloria Domínguez-Bello2016PresentationAnglais
W6.4 Second year of life platform and monitoring systemsJan Grevendonk2016PresentationAnglais
W6.3 Protecting Lives in the 2nd Year of Life (2YL) in GhanaAbigail Shefer2016PresentationAnglais
W6.2 Raising the Profile of an 18-month Well-child Visit: the 2YL PlatformElicah Kandinda Kamiji2016PresentationAnglais
W6.1 Global landscape analysis and literature review of 2nd year of life immunization platformImran Mirza2016PresentationAnglais
W6.0 Intro: Establishing a Second-year-of-life (2YL) Healthy Child VisitRudi Eggers2016PresentationAnglais
W6 Immunization in the Second Year of LifeRebecca Fields2016ReportAnglais
W5.3 Good Participatory Practices for Vaccine Clinical TrialsNelson Michael2016PresentationAnglais
W5.2 African Vaccine Regulatory Forum (AVAREF): New Vision and Blueprint for Ethics and Regulatory Capacity Strengthening in AfricaDicky Akanmori2016PresentationAnglais
W5.1 WHO Regulatory Strengthening Update & LMICs Challenges in Vaccine Clinical Trial RegulationWilliam Wekwete2016PresentationAnglais
W5 Regulatory Challenges and Constraints When Evaluating Vaccine Clinical TrialsKlaus Cichutek2016ReportAnglais
W4.6 Vaccines for healthcare pathogens: No ESKAPEJordi Rello2016PresentationAnglais
W4.5 Gonococcal antimicrobial resistance and vaccinesMagnus Unemo2020PresentationAnglais
W4.4 Vaccines to prevent antibiotic-resistant Staphylococcus aureus (MRSA) infectionsOlaf Schneewind2016PresentationAnglais
W4.3 The Role of Vaccines in Antimicrobial Resistance StrategiesBruce Gellin2016PresentationAnglais
W4.2 WHO Global Action Plan on Antimicrobial ResistanceMartin Friede2016PresentationAnglais
W4.1 Introduction: Antimicrobial Resistance & VaccinesA. A. Adeyemo2016PresentationAnglais
W3.4 Vaccine technology costs and health impact assessment toolMercy Mvundura2016PresentationAnglais
W3.3 Microarray patch case study: Measles-rubella vaccineDarin Zehrung2016PresentationAnglais
W3.2 Total System EffectivenessTina Lorenson2016PresentationAnglais
W3.1 Introduction: Total Systems EffectivenessTina Lorenson2016PresentationAnglais
W2.2 Public Health Criteria for Dengue Vaccine Risk/Benefit Assessment and Risk ManagementPeter Smith2016PresentationAnglais
W11.4 Applying TIP to low and middle income settings: a case study from South AfricaNicola Christofides and Janine Simon-Meyer2016PresentationAnglais
W11.3 Tailoring Immunization Programmes (TIP): An example of tailoring communication on vaccinations targeting hard.to.serve communities in SwedenAnn Lindstrand2016PresentationAnglais
W11.2 Vaccine Hesitancy: Determining the scale of the challengeSusan Goldstein2016PresentationAnglais
W11.1 Vaccine Hesitancy: what it means and what we need to know in order to tackle itRobb Butler2016PresentationAnglais
W10.4 Rabies antibodies for Passive Post-exposure prophylaxisTsepo Tsekoa2016PresentationAnglais
W10.3 Gene-based Delivery of Broadly Neutralizing Antibodies for HIV PreventionWayne Koff2016PresentationAnglais
W10.2 Passive vaccination as a global strategy for preventing RSV disease in infantsFilip Dubovsky2016PresentationAnglais
W10.1 Monoclonal antibodies for infectious diseasesMartin Friede2016PresentationAnglais
W1.3 Design of self-assembling protein nanomaterials as next.generation vaccine scaffoldsNeil King2016PresentationAnglais
W1.2 Epitope-focused vaccine designBill Schief2016PresentationAnglais
W1.1 Structural studies of viral envelope proteins and insights for vaccine designFelix Rey2016PresentationAnglais
W1.0 Introduction: Applying Novel Technologies to Vaccine DevelopmentRino Rappuoli2016PresentationAnglais
W9 Gavi's Vaccine Investment Strategy (VIS)Helen Rees2016ReportAnglais
W8 Combination Vaccines: Why and How?A. A. Adeyemo2016ReportAnglais
P6.4 Preferred Product CharacteristicsDavid Kaslow2016PresentationAnglais
P6.3 Schistosomiasis Vaccine UpdatesAnnie Mo2016PresentationAnglais
P6.2 Vaccine development for Group A StreptococcusAndrew Steer2016PresentationAnglais

Ajouté par: Angela Hwang

Ajouté le: 2022-08-04 08:29:10

Consultations: 1720

Fichier téléchargé

W9GaviVIS.pdf

Cliquez pour télécharger

Ajouter une ressource